<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01719640</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-BMMNC-DM</org_study_id>
    <nct_id>NCT01719640</nct_id>
  </id_info>
  <brief_title>MSC and BMMNC in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Autologous Bone Marrow Mesenchymal Stem Cell and Bone Marrow Mononuclear Cell Infusion in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuzhou General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cell injury in human islets induced by non-immune mediated inflammation occur in vitro upon&#xD;
      hyperglycemia in type 2 diabetes mellitus. Infusion of autologous bone marrow mononuclear&#xD;
      cells (BMMNCs) is an emerging therapeutic approach for DM, which showed promising outcomes&#xD;
      with mild side effects. Infusion of BMMNCs and autologous bone marrow mesenchymal stem cells&#xD;
      in combination might exert enhanced repairing effects. We hypothesized that infusion of these&#xD;
      two classes of cells might provide multiple signals for regeneration and improve recovery&#xD;
      from inflammation-induced lesion. The effects might be maximized by intra-arterial pancreatic&#xD;
      infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>1y</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>exogenous insulin requirements</measure>
    <time_frame>1y</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting hemoglucose</measure>
    <time_frame>1y</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting c-peptide</measure>
    <time_frame>1y</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events related to the stem cell infusion procedure</measure>
    <time_frame>1y</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BMMSC+BMMNC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion of BMMSC+BMMNC and insulin injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMMNC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>infusion of BMMNC and insulin injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>insulin injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infusion of BMMSCs</intervention_name>
    <description>infusion of BMMSCs</description>
    <arm_group_label>BMMSC+BMMNC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infusion BMMNCs</intervention_name>
    <description>infusion of BMMNCs</description>
    <arm_group_label>BMMNC</arm_group_label>
    <arm_group_label>BMMSC+BMMNC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin</intervention_name>
    <description>intensive insulin care</description>
    <arm_group_label>BMMNC</arm_group_label>
    <arm_group_label>BMMSC+BMMNC</arm_group_label>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent.&#xD;
&#xD;
          -  Mentally stable and able to comply with the procedures of the study protocol.&#xD;
&#xD;
          -  Clinical history compatible with type 2 diabetes (T2DM) as defined by the Expert&#xD;
             Committee on the Diagnosis and classification of Diabetes Mellitus&#xD;
&#xD;
          -  Onset of T2DM disease at ≥ 35 years of age.&#xD;
&#xD;
          -  T2DM duration ≥ 3 and ≤ 20 years at the time of enrollment.&#xD;
&#xD;
          -  Basal C-peptide 0.3-2.0 ng/mL&#xD;
&#xD;
          -  HbA1c ≥ 7.5 and ≤ 12% before standard medical therapy (SMT). Patients must have been&#xD;
             treated with SMT for minimum of 4 months prior to randomization.&#xD;
&#xD;
        Insulin dose and metformin doses should be stable over the 3 months prior to randomization.&#xD;
&#xD;
          -  HbA1c ≥ 7.5 and ≤ 9.5% at time of randomization.&#xD;
&#xD;
          -  Total insulin daily dose (TDD) at time of randomization should not exceed 1.0&#xD;
             units/day/kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt;35 kg/m2.&#xD;
&#xD;
          -  Insulin requirements of &gt; 100 U/day.&#xD;
&#xD;
          -  HbA1c &gt;9.5%. (at the time of randomization)&#xD;
&#xD;
          -  C-reactive protein (hs-CRP) &gt;3.00&#xD;
&#xD;
          -  Uncontrolled blood Pressure: SBP &gt;160 mmHg or DBP &gt;100 mmHg at the time of&#xD;
             randomization.&#xD;
&#xD;
          -  Evidence of renal dysfunction, serum creatinine &gt; 1.5 mg/dl (males) and 1.4 mg/dl&#xD;
             (females).&#xD;
&#xD;
          -  Proteinuria &gt; 300 mg/day&#xD;
&#xD;
          -  Evidence of cardiovascular disease, existing congestive cardiac failure on physical&#xD;
             exam and/or acute coronary syndrome in past 6 months.&#xD;
&#xD;
          -  For female participants: Positive pregnancy test, presently breast-feeding, or&#xD;
             unwillingness to use effective contraceptive measures for the duration of the&#xD;
             study.For male participants: intent to procreate 3 months before or after the&#xD;
             intervention or unwillingness to use effective measures of contraception. Oral&#xD;
             contraceptives,Norplant®, Depo-Provera®, and barrier devices with spermicide are&#xD;
             acceptable contraceptive methods; condoms used alone are not acceptable&#xD;
&#xD;
          -  Active infection including hepatitis C, HIV, or TB as determined by a positive skin&#xD;
             test or clinical presentation, or under treatment for suspected TB. Positive tests are&#xD;
             acceptable only if associated with a history of previous vaccination in the absence of&#xD;
             any sign of active infection. Positive tests are otherwise not acceptable, even in the&#xD;
             absence of any active infection at the time of evaluation&#xD;
&#xD;
          -  Known active alcohol or substance abuse including cigarette/cigar smoking&#xD;
&#xD;
          -  Baseline Hgb below the lower limits of normal at the local laboratory; lymphopenia&#xD;
             (&lt;1,000/L), neutropenia (&lt;1,500/L), or thrombocytopenia (platelets &lt;100,000/L).&#xD;
&#xD;
          -  A history of Factor V deficiency or other coagulopathy defined by INR &gt;1.5, PTT&gt;40, PT&#xD;
             &gt;15.&#xD;
&#xD;
          -  Any coagulopathy or medical condition requiring long-term anticoagulant therapy(e.g.,&#xD;
             warfarin) after transplantation (low-dose aspirin treatment is allowed) or patients&#xD;
             with an INR &gt;1.5.&#xD;
&#xD;
          -  Acute or chronic pancreatitis.&#xD;
&#xD;
          -  Symptomatic peptic ulcer disease.&#xD;
&#xD;
          -  Hyperlipidemia despite medical therapy (fasting LDL cholesterol &gt;130 mg/dl, treated or&#xD;
             untreated; and/or fasting triglycerides &gt; 200 mg/dl).&#xD;
&#xD;
          -  Receiving treatment for a medical condition requiring chronic use of systemic&#xD;
             steroids.&#xD;
&#xD;
          -  Symptomatic cholecystolithiasis.&#xD;
&#xD;
          -  Use of any investigational agents within 4 weeks of enrollment.&#xD;
&#xD;
          -  Admission to hospital for any reason in the 14 days prior to enrollment (signing&#xD;
             consent).&#xD;
&#xD;
          -  Presence of active proliferative diabetic retinopathy or macular edema&#xD;
&#xD;
          -  Any malignancy&#xD;
&#xD;
          -  Abnormal liver function &gt;1.5 x ULN&#xD;
&#xD;
          -  Abdominal aortic aneurysm&#xD;
&#xD;
          -  History of cerebro-vascular accident&#xD;
&#xD;
          -  Any patient with acute or subacute decompensation from diabetes&#xD;
&#xD;
          -  Any acute or chronic infectious condition that in the criteria of the investigator&#xD;
             would be a risk for the patient.&#xD;
&#xD;
          -  Subjects with hypoproteinemia, cachexia or terminal states&#xD;
&#xD;
          -  Subjects with history of anorexia/bulimia&#xD;
&#xD;
          -  Subjects with respiratory insufficiency&#xD;
&#xD;
          -  Subjects that are being treated with any medication that could interfere with the&#xD;
             outcome of the study such as: Sulfonylureas, Thiazolidinediones and glucagon like&#xD;
             peptide 1 (GLP-1) analogues (Exenatide, Byetta), Pramlintide (Amylin),&#xD;
             Dipeptidylpeptidase IV (DPP-IV) inhibitors (i.e. Sitagliptin, Januvia)&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, will interfere with&#xD;
             thesafe completion of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuzhou General Hospital, Xiamen Univ</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>October 6, 2012</study_first_submitted>
  <study_first_submitted_qc>October 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fuzhou General Hospital</investigator_affiliation>
    <investigator_full_name>Jianming Tan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>bone marrow mononeclear cells</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

